NFA
TEVA icon

Nuveen Fund Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Nuveen Fund Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,002
Closed -$194K – 338
2017
Q3 		$194K Sell
11,002
-1,667
-13% -$37.5K 0.04% 342
2017
Q2 		$402K Sell
12,669
-4,840
-28% -$150K 0.06% 297
2017
Q1 		$562K Sell
17,509
-71
-0.4% -$2.42K 0.07% 270
2016
Q4 		$637K Sell
17,580
-4,583
-21% -$183K 0.09% 250
2016
Q3 		$1.02M Buy
22,163
+210
+1% +$11K 0.14% 187
2016
Q2 		$1.1M Buy
+21,953
New +$1.17M 0.17% 168

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Nuveen Fund Advisors's TEVA Position: Q4 2017 in Review

Nuveen Fund Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 11,002 shares — an estimated $194K sold.

Nuveen Fund Advisors first reported a position in TEVA in Q2 2016 and held it in 6 quarters. The position peaked at $1.1M in Q2 2016. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Nuveen Fund Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nuveen Fund Advisors sold 11,002 Teva Pharmaceuticals shares in Q4 2017, an estimated $194K.
  • Nuveen Fund Advisors first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Nuveen Fund Advisors's Teva Pharmaceuticals position peaked at $1.1M in Q2 2016.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Nuveen Fund Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.